SCHEMBL3092207

SCHEMBL3092207

NC(=O)[C@H]1[C@H](CS)N(Cc2ccccc2)C(=O)N1Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.44
CYP2C19 P33261 3/20 0.41
CYP2C9 P11712 2/20 0.41
KMT2A Q03164 3/20 0.41
F2 P00734 1/20 0.39
PLG P00747 1/20 0.39
ELANE P08246 1/20 0.39
CTSG P08311 1/20 0.39
CMA1 P23946 1/20 0.39
CTRC Q99895 1/20 0.39
EP300 Q09472 1/20 0.38
BRD4 O60885 1/20 0.37
SIRT1 Q96EB6 1/20 0.37
MEN1 O00255 1/20 0.37
CAPN1 P07384 1/20 0.37
POLB P06746 1/20 0.36
CYP2D6 P10635 1/20 0.36
FPR1 P21462 1/20 0.36
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3084318 0.88 EHMT2 (0.46) EHMT2CYP2C19CYP2C9KMT2AF2
SCHEMBL9679741 0.88 EHMT2 (0.46) EHMT2CYP2C19CYP2C9KMT2AF2
SCHEMBL3095764 0.84 EHMT2 (0.43) EHMT2CYP2C19CYP2C9KMT2AF2
SCHEMBL3095771 0.84 EHMT2 (0.43) EHMT2CYP2C19CYP2C9KMT2AF2
SCHEMBL9679618 0.80 EHMT2 (0.42) EHMT2CYP2C19CYP2C9KMT2AF2
SCHEMBL9481636 0.79 EHMT2 (0.49) EHMT2CYP2C19KMT2AF2PLG
SCHEMBL9488883 0.79 EHMT2 (0.49) EHMT2CYP2C19KMT2AF2PLG
SCHEMBL28746099 0.77 EHMT2 (0.41) EHMT2CYP2C19CYP2C9KMT2AF2
SCHEMBL351271 0.76 EHMT2 (0.56) EHMT2CYP2C19CYP2C9KMT2AF2
SCHEMBL22130803 0.76 EHMT2 (0.56) EHMT2CYP2C19CYP2C9KMT2AF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7799929-B2 Biotin intermediate and process for preparing the same TANABE SEIYAKU CO., LTD. (JP) 2010-09-21 US disclosed
EP-1462444-B1 INTERMEDIATE FOR BIOTIN AND PROCESS FOR PRODUCING THE SAME MITSUBISHI TANABE PHARMA CORP (JP) 2009-09-16 EP disclosed
EP-2098528-A2 Biotin intermediate and process for preparing the same Mitsubishi Tanabe Pharma Corporation (JP) 2009-09-09 EP disclosed
US-20080119655-A1 Biotin intermediate and process for preparing the same SEKI MASAHIKO 2008-05-22 US disclosed
US-7335778-B2 Intermediate for biotin and process for producing the same TANABE SEIYAKU CO., LTD. (JP) 2008-02-26 US disclosed
US-20050038260-A1 Intermediate for biotin and process for producing the same API CORPORATION (JP) 2005-02-17 US disclosed
EP-1462444-A1 INTERMEDIATE FOR BIOTIN AND PROCESS FOR PRODUCING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2004-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119655-A1 Biotin intermediate and process for preparing the same BTD, BOLA2; BOLA2B, BCAT1 EHMT2 308/4885CYP2C19 1325/4885CYP2C9 1193/4885
US-20050038260-A1 Intermediate for biotin and process for producing the same BTD, BCAT1, HLCS EHMT2 388/4885CYP2C19 1208/4885CYP2C9 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.